Haematological parameter evaluation in different types of deletional alpha thalassaemia and in coinheritance of deletional alpha thalassaemia and beta thalassaemia in Hospital Universiti Sains Malaysia by Arifin, Samilawati Mohd
HAEMATOLOGICAL PARAMETER EVALUATION IN DIFFERENT 
TYPES OF DELETIONAL ALPHA THALASSAEMIA AND IN 
COINHERITANCE OF DELETIONAL ALPHA THALASSAEMIA AND 















Dissertation Submitted In Partial Fulfillment Of The Requirements 










All praises to Allah S.W.T the Most Merciful and the Most Beneficent. 
 
First of all, I would like to express my thankfulness to Allah S.W.T for His blessing and for 
giving me strength to complete my research successfully within the given time. 
 
I wish to take this opportunity to express my appreciation to helpful and knowledgeable 
supervisor, Associate Prof. Dr Rosnah Bahar, whom I deeply indebted for her continuous 
supervision and care in the process of finishing this study. Without her excellent guidance, 
caring, patience as well as continuous encouragement, I would never be able to write this 
dissertation completely. 
 
With great pleasure, I would like to acknowledge Dr Marini Ramli, my co-supervisor for her 
helps, ideas and continuous support.  
 
Also, a million thanks to all medical laboratory technologists in haematology department of 
HUSM who involves direct or indirectly in this study process.  
 
Most importantly, my special appreciation goes to my beloved husband, Akmal Azrin bin 
Ariffin, my son, Azad Syazwan as well as my daughters, Azra Syaziya and Azzahra Syaifa for 
their sacrifice, countless loves, understanding and patience throughout my study. Last but not 
least, I would like to express my deepest appreciation to my family members and friends, for 










Table of contents iii-vi 
List of tables vii-viii 
List of figures ix-x 
List of abbreviations xi-xv 
Abstract (Malay language) xvi-xvii 
Abstract (English) xviii-xix 
Chapter 1 : General Introduction 2-4 
Chapter 2 : Literature Review 5 
2.1 Normal human haemoglobin 6-7 
 2.1.1 Genetic control of human haemoglobin 7-9 
2.2 Inherited haemoglobin disorders 9 
2.3 Alpha thalassaemia 10 
 2.3.1 Pathophysiology of α thalassaemia 10 
 2.3.2 Types of deletional α thalassaemia and its worldwide distribution 10-12 
 2.3.3 Genotypic and phenotypic characteristics of α thalassaemia 12-13 
    
iv 
 
2.4 Beta thalassaemia 13 
 2.4.1 Pathophysiology of  β thalassaemia 14 
 2.4.2 Types of β thalassaemia and its worldwide distribution 14-15 
 2.4.3 Genotypic and phenotypic characteristics of β thalassaemia 15-16 
2.5 Effect of coinheritance for thalassaemia 16-17 
2.6 Prevalence of thalassaemia 18 
 2.6.1 Prevalence of thalassaemia in Malaysia 18-19 
 2.6.2 α thalassaemia in Malaysia 19-20 
 2.6.3 β thalassaemia in Malaysia 20 
2.7 Disease burden 21-23 
2.8 Screening programme 23 
 2.8.1 Screening tests 24 
 2.8.1(a) Full blood count (FBC) and peripheral blood film 24 
 2.8.1(b) HbH inclusion test 25 
 2.8.1(c) Haemoglobin electrophoresis 25-26 
 2.8.1(d) High Performance Liquid Chromatography (HPLC) 26-28 
 2.8.1(e) Molecular analysis 28-29 
 2.8.2 Screening programme in Malaysia 29-31 
 2.8.3 Current screening algorithm 31-32 
v 
 
Chapter 3 : Objective  
3.1 Objective of the study  
 3.1.1 General objective 35 
 3.1.2 Specific objectives 35 
3.2 Research hypotheses 35 
Chapter 4 : Research Methodology  
4.1 Study design 37 
4.2 Study sample 37 
4.3 Study frame 37 
4.4 Inclusion criteria 37 
4.5 Sample size calculation 38-39 
4.6 Data collection, sample handling and storage 40 
4.7 Laboratory methods 40 
 4.7.1 Full blood count (FBC) 40-44 
 4.7.2 Full blood picture 44-45 
 4.7.3 Alkaline gel electrophoresis 45-48 
 4.7.4 High Performance Liquid Chromatography (HPLC) 49-52 
 4.7.5 Molecular study for deletional α thalassaemia 52 
 4.7.5(a) DNA extraction 52-53 
vi 
 
 4.7.5(b) Multiplex Gap Polymerase Chain Reactions (PCR) 54 
 4.7.6 Molecular study for beta thalassemia by using Multiplex 
Amplification Refractory Mutation System- Polymerase Chain 
Reaction (MARMS-PCR) 
54-57 
 4.7.6(a) Multiplex Amplification Refractory Mutation System- Polymerase 
Chain Reaction (Multiplex ARMS-PCR) protocol 
58 
4.8 Study Flow Chart 59 
4.9 Statistical Analysis 60 
Chapter 5 : Results 62-72 
Chapter 6 : Discussion 74-82 
Chapter 7 : Limitation 84 
Chapter 8 : Conclusion 86 
References 88-95 
Appendices  
APPENDIX A Study protocol approval by Jawatankuasa Etika Penyelidikan 
Manusia Universiti Sains Malaysia (JEPeM-USM) 
96-98 




 July 2017 at 
Hilton Hotel, Kuala Lumpur 
99-100 






LIST OF TABLES 
  Page 
Table 2.1 Haemoglobins normally present during adult, foetal and embryonic 
periods of life 
7 
Table 2.2  Estimated cost for monitoring, treatment and complications 
monitoring of thalassaemia. 
21 
Table 2.3 The cost for different types of iron chelation therapy. 22 
Table 4.1 Sample size calculation by using 2 mean formula, to compare mean 
haematological parameters in various spectrum of deletional α 
thalassaemia 
38 
Table 4.2 Sample size calculation by using 2 mean formula, to compare mean 
haematological parameters in coinheritance of deletional α 
thalassaemia and β thalassaemia 
39 
Table 4.3 Sequences primer for Multiplex ARMS-PCR and ARMS PCR 55-56 
Table 5.1 Characteristics of samples profile 62 
Table 5.2  Characteristics of deletional α thalassaemia cases 64 
Table 5.3  Distribution of deletional α thalassaemia cases according to 
spectrum 
65 
Table 5.4  Distribution of various spectrum of α thalassaemia according to 
gender 
65 





Table 5.6 Proportion of coinheritance cases 66 
Table 5.7 Distribution of β gene mutation cases 66 
Table 5.8  Distribution of spectrum of α deletion and β gene mutation in 
coinheritance cases 
67 
Table 5.9 Haematological parameters comparison between deletional α 
thalassaemia group and normal group 
68 
Table 5.10  The comparison of haematological parameters between the 
commonest 3 types of deletional α thalassaemia 
69 
Table 5.11  The comparison of haematological parameters in coinheritance of α 




















LIST OF FIGURES 
  Page 
Figure 2.1 The schematic representation of different combination of α and β 
globin at different stages of life and haemoglobin types produced 
7 
Figure 2.2 Schematic representation of the human α globin gene clusters 8 
Figure 2.3 Schematic representation of the human β globin gene clusters 8 




Figure 2.5 The genetics of α thalassaemia 13 
Figure 2.6 Algorithm for iron chelation in transfusion dependent thalassaemia 22 
Figure 2.7 Haemoglobin inclusion test showing golf ball appearance 25 
Figure 2.8 Normal haemoglobin analysis by HPLC 27 
Figure 2.9 Algorithm for voluntary and cascade screening 31 
Figure 4.1 Impedance principle with hydrodynamic focusing 42 
Figure 4.2 Schematic representation of automated HCT measurement using 
cumulative pulse height detection 
43 
Figure 4.3 Red cell histogram illustrating RDW and platelet count concept 44 
Figure 4.4 The schematic representation of interpretation of alkaline gel 
electrophoresis method 
49 
Figure 4.5 The purification procedure for DNA extraction by using 
NucleoSpin
®




Figure 4.6  The schematic presentation of location of various primers for 
multiplex-ARMS PCR and ARMS PCR and mutations site within 
HBB gene 
57 
Figure 4.7 Flow chart of methodology 59 

























LIST OF ABBREVIATIONS 




 3D Three dimensional 
ARMS-PCR Amplification Refractory Mutation System- Polymerase Chain Reaction 
Aγ A-gamma 
bp Base pair 
CE Capillary Electrophoresis 
CV Coefficient of variance 
dl Deciliter 
DNA Deoxyribonucleic acid  
DPX Dibutylphthalate Polystyrene Xylene 
EDTA Ethylenediaminetetraacetic acid  
FBC Full blood count 
--
FIL






Hb Bart Haemoglobin Bart 
xii 
 
HbA Haemoglobin A 
HbA2 Haemoglobin A2 
HBB Beta globin gene 
HbC Haemoglobin C 
HbCS Haemoglobin constant spring 
HbD Haemoglobin D 
HbE Haemoglobin E 
HbF Haemoglobin F 
HbG Haemoglobin G 
HbH Haemoglobin H 
HbO Haemoglobin O 
HbS Haemoglobin S 
Hct Haematocrit 
HPLC High Performance Liquid Chromatography  
HUSM Hospital Universiti Sains Malaysia 
IMR Instituted Medical Research 
kb Kilobase 
MCH Mean Corpuscular Haemoglobin 
MCHC Mean Corpuscular Haemoglobin Concentration 
xiii 
 
MCV Mean Corpuscular Volume  
--
Med





Magnetic Resonance Imaging 
messenger RNA  
PCR Polymerase Chain Reaction 
pg Picograms 
RBC Red Blood Cell 
RDW Red cell distribution width 
RM Ringgit Malaysia 
RNA Ribonucleic acid 
SEA South East Asia 
--
SEA
 South East Asian type α
0
 
SLS Sodium Lauryl Sulphate 
--
THAI
 Thailand type α
0
 















 Alpha zero  
α2β2 Haemoglobin A 
α2γ2 Haemoglobin F 
α2δ2 Haemoglobin A2 
α2ε2 Haemoglobin Gower 2 
α-
3.7
 Rightward 3.7 kb gene deletion 
α-
4.2
 Leftward 4.2 kb gene deletion 
Β Beta 
β/β Normal functional beta globin chain 
β
+












































δ2γ2 Haemoglobin Portland 
























PENILAIAN TERHADAP PARAMETER HEMATOLOGI DALAM PELBAGAI KES 
PENGHAPUSAN ALFA THALASSEMIA DAN DALAM KES WARISAN BERSAMA 






Alfa thalassemia merupakan salah satu penyakit genetik yang biasa dijumpai di Malaysia dan 
merupakan satu isu kesihatan awam. Kaedah saringan yang efektif adalah elemen penting dalam 
Program Pencegahan dan Kawalan Thalassemia bagi mengesan semua kes-kes thalassemia 
secara efektif serta memaksimumkan penggunaan sumber.  
 
Tujuan kajian ini adalah untuk mengenal pasti hubungkait antara parameter hematologi dalam 
kes-kes penghapusan alfa thalassemia dan juga warisan bersama alfa dan beta thalassemia 
terhadap parameter hematologic di kalangan pesakit-pesakit di HUSM. 
 
Satu kajian keratan rentas dengan ulasan rekod retospektif pada 214 sampel yang dihantar ke 
unit Hematologi, HUSM telah dijalankan dengan kebenaran daripada Pengarah HUSM. Data 
dianalisis bagi melihat perkaitan antara indeks darah merah dalam pelbagai spektrum alfa 
thalassemia dan kes perwarisan bersama alfa dan beta thalassemia.   
 
Tujuh puluh satu (71) kes telah dikesan mempunyai penghapusan alfa thalassemia. Jenis yang 
paling kerap dijumpai ialah jenis South-East Asian (SEA), iaitu 50.7%. Sebanyak 13.8% kes 
perwarisan bersama alfa dan beta thalassemia telah dikesan dengan jenis perwarisan bersama 
yang paling kerap dijumpai adalah antara SEA heterozygous dengan mutasi pada Codon 26  




Terdapat perbezaan yang ketara pada nilai RBC, MCV dan MCH dikalangan subjek yang 
mempunyai masalah penghapusan alfa thalassemia berbanding dengan subjek yang mempunyai 
normal siasatan molecular (nilai p < 0.001). Subjek yang mempunyai penghapusan alfa 
thalassemia menunjukkan paras  median MCH < 20.8 fL. Nilai MCV dan kiraan RBC memberi 
nilai tambahan dalam membezakan kumpulan ini dan membantu dalam diagnosis sekiranya 
teknik molekular tidak boleh didapati.  
 
Parameter hematologi yang ketara termasuk kepekatan hemoglobin, MCV, MCH, RDW dan 
kiraan platelet diperhatikan diantara 3 spektrum penghapusan alfa thalassemia yang paling 
kerap dijumpai iaitu antara 3.7 heterozygous, SEA heterozygous dan 3.7 bersama SEA 
heterozygous. Parameter-parameter ini boleh digunakan sebagai saringan sebelum ujian 


















HAEMATOLOGICAL PARAMETER EVALUATION IN DIFFERENT TYPES OF 
DELETIONAL ALPHA-THALASSAEMIA AND IN COINHERITANCE OF 




Alpha thalassaemia is a common genetic disorder in Malaysia and is a public health problem. 
Effective screening tool is an essential element in Thalassaemia Prevention and Control 
Programme to effectively detect all cases of thalassaemia and to maximize the resources. 
 
The aim of this study was to evaluate the haematological parameters in various types of 
deletional alpha (α) thalassaemia and effect of coinheritance with beta (β) thalassaemia towards 
the haematological parameters among patients in Hospital Universiti Sains Malaysia (HUSM), 
Kelantan, Malaysia. 
 
A cross-sectional study with retrospective record review on 214 samples sent to Molecular Unit, 
Hematology Unit, HUSM was conducted. A permission from Director of HUSM was obtained. 
The data was analyzed to study the red cell indices (haemoglobin concentration, red blood cell 
(RBC) count, mean corpuscular volume (MCV), mean corpuscular haemoglobin (MCH), red 
cell distribution width (RDW) and platelet count in various spectrum of α thalassaemia and in 
coinheritance cases. 
 
Seventy one (33.2%) cases were detected to have deletional α thalassaemia. The most common 
type detected was South-East Asian (SEA) type deletion (αα/--
SEA
), α thalassaemia (50.7%). 
Coinheritance of α thalassaemia with β thalassaemia/haemoglobinopathy was seen in 13.8% of 
xix 
 
cases with the most common coinheritance was seen between SEA heterozygous (αα/--
SEA
) with 
codon 26 mutation (HbE).  
 
There were significant differences of RBC count, MCV and MCH level in patients with 
deletional α thalassemia compared to group without α gene deletion (p-value < 0.001). 
Deletional α thalassaemia cases showed median MCH level of 20.8 fL. The MCV and RBC 
counts gave an added value in differentiating between the group and might aid in making the 
diagnosis if the molecular technique is not available.  
 
Significant haematological differences include haemoglobin concentration, MCV, MCH, RDW 
and platelet count were observed among 3 commonest spectrum of deletional α thalassaemia 
which is between 3.7 heterozygous, SEA heterozygous and 3.7 heterozygous with SEA 
heterozygous. The parameters can be used as a good screening tool before persuing molecular 






































1.0 GENERAL INTRODUCTION 
 
Thalassaemia is a hereditary disease in which there is reduce or absent in production of the 
globin chains of haemoglobin. It is an increasing global health problem. It has been estimated 
that approximately 7% of the world population are carriers of such disorders and that 300 000 – 
400 000 babies with severe forms of this disease are born each year (Weatherall and Clegg, 
2001). In South East Asia (SEA) region, thalassaemia and haemoglobinopathies are the most 
common genetic disorders which have a tremendous psychological, social, financial and health 
economic burden to the country. Alpha (α) thalassaemia, beta (β) thalassaemia, haemoglobin E 
(HbE) and haemoglobin constant spring (HbCS) are prevalent in this region.  
 
In Malaysia, α thalassaemia is a public health concern, with a frequency of 51.2% (Ahmad et 
al., 2013). According to Malaysian Thalassaemia Registry 2017, a total of 7220 patients with 
thalassaemia are registered with 2611 cases are β thalassaemia major, 2402 cases of compound 
heterozygous HbE/β thalassaemia, 733 cases of thalassaemia intermedia, 1022 cases of 
haemoglobin H (HbH) disease and 452 cases with other diagnosis. Out of this figure, 5013 cases 
are transfusion dependent thalassaemia, with diagnosis of β thalassaemia major and HbE/β 
thalassaemia (Malaysian Thalassemia Registry, May 2017).  
 
The disease is a burden to our country as well as to the patients and family members. About RM 
3 million are spent for treatment of thalassaemia major patient until they reach age of 30 years 
old. Prevention strategy to reduce this disease is important and is more cost effective. Reducing 
the birth of transfusion dependent thalassaemia patients by an effective screening strategy is 
important considering the cost needed for the optimal care of affected patients as well as socio 
economic burden to patients, family members and government.  
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Current algorithm for voluntary and cascade screening in Malaysia is including walk in and 
cascade screening. This screening strategy is mainly targeting the antenatal, pre-marital and 
adolescences group (secondary Form 4 students) which recently had been implemented. The 
haematological parameters is used as first laboratory screening tool before other diagnostic test 
including peripheral blood smear, haemoglobin analysis, Deoxyribonucleic acid (DNA) analysis 
is carried out for a definitive diagnosis (Ministry Of Health, 2009).  
 
In α thalassaemia, the haematological parameters were correlated with the number of α globin 
genes affected (Akhavan-Niaki et al., 2012; Clarke and Higgins, 2000). The degree of 
microcytosis and number and type of α gene deletions were correlated, with --/αα genotype 
associated with the lowest mean corpuscular volume (MCV), followed by the -α/-α genotype, 
and then the -α/αα genotype, while the red blood cells (RBC) counts showed the reverse trend 
(Wang et al., 2000). However, currently, in our practice, the correlation between the number of 
gene deletion and the degree of microcytosis is not clearly seen. The findings might be due to 
the high prevalence of nutritional deficiencies in our country, which may not be similar with the 
findings in other countries. In an area where α thalassaemia is prevalent, an effective screening 
parameters to differentiate it from other condition is mandatory as a cost effective way to make 
the preventive programme a success. Other than that, an efficient screening parameters to 
discriminate the genotypes of α thalassaemia for a judicious selection of patients for molecular 
testing of α thalassaemia is helpful to reduce the unnecessary cost of diagnostic investigations.  
 
Besides that, in cases coinheritance of thalassaemia, the haematological parameters as well as 
the amount of the variant haemoglobin presence may be altered. This may lead to misdiagnosis 




A safe haematological parameters cut-off value for thalassaemia screening in area of nutritional 
deficiencies as well as thalassaemia are highly prevalent need to be established,  as the 




















































2.0 LITERATURE REVIEW 
 
2.1 Normal human haemoglobin 
 
Haemoglobin is a red cell pigment, functions as an oxygen carrier for carbon dioxide exchange 
at tissues level. Each red cell contains approximately 640 million haemoglobin molecules. A 
molecule of haemoglobin is made up from 4 haem groups linked to 4 globin chains and carries 4 
oxygen molecules. The synthesis of various globin chains is started during embryonal life and 
undergo a major switch to adult haemoglobin 3 to 6 months after birth (Weatherall, 2004). It 
varies according to oxygen requirement in different stages of life. In embryonic life, the 
haemoglobins are composed of combination between α-like globin called zeta (δ)  globin with 
gamma (γ) globin producing haemoglobin Portland (δ2γ2) and δ globin with epsilon (ε) globin 
producing haemoglobin Gower 1 (δ2ε2) and combination of α globin with ε globin producing 
haemoglobin Gower 2 (α2ε2). In foetal life, haemoglobin F (HbF) (α2γ2) is predominant. In 
adults,  haemoglobin A (HbA) (α2β2) comprises more than 95% of total haemoglobin while  
haemoglobin A2 (HbA2) (α2δ2) is present as minor component in red blood cells (Givens Bell, 
1999). The different combination of the globin chains and type of haemoglobin produced from 
foetal life until adult life are showed in Figure 2.1 and Table 2.1. Under normal circumstances, 
the red cells of an adult human contains approximately 97-98% of HbA, 2-3% of HbA2 and 








Table 2.1. Haemoglobins normally present during adult, foetal and embryonic periods of life. 
Adapted from (Bain, 2008) 
Haemoglobin species Globin chains Period when normally present 
A α₂β₂ Major haemoglobin in adult life 
A2 α₂δ₂ Minor haemoglobin in adult life 
F α₂ γ₂ Minor haemoglobin in adult life, major 
haemoglobin in foetal life with a declining 
percentage through the neonatal period 
Gower 1 δ₂ε₂ Significant haemoglobin during early 
intrauterine life 
Gower 2 α₂ε₂ Significant haemoglobin during early 
intrauterine life 
Portland δ₂ γ₂ Significant haemoglobin during early 
intrauterine life 
 
Figure 2.1. The schematic representation of different combination of α and β globin at different 
stages of life and haemoglobin types produced. Adapted from (Cunningham et al., 2014)  
 
2.1.1 Genetic control of human haemoglobin 
Each type of globin chain is controlled by distinct genes. There are 2 genes controlling α and γ 
chain, while 1 gene for each other globin chains. The specific regions that control the 
production of this different globin chains have been determined (Weatherall and Clegg, 2008). 
The α-like and β-like globin chain is regulated by clusters of gene located at chromosome 16 
and chromosome 11 respectively. The α-like globin gene is located close to telomere of 
chromosome 16 (16p13.3). The functional genes are arranged along the chromosome in the 
order of telomere-δ-α2-α1-centromere surrounded by widely expressed genes as shown in Figure 
2.2. Upstream of this α-gene cluster, there are 4 highly conserved non-coding sequences or 
multispecies conserved sequences (MCS) called MCS R1-R4. The only sequence shown to be 
essential for α globin gene expression is MCS R2, also known as HS-40 (Higgs et al., 1998). 
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The key erythroid transcription factors and its various co-factors progressively bind to the 
upstream elements and the promoters of the α-like gene as the haematopoietic progenitor cells 
commit into erythroid lineages and begin to differentiate into mature red blood cells. RNA 
polymerase II is recruited to both the upstream elements and promoter of α-globin as 
transcription starts in early erythroid progenitors. The upstream elements and promoters of α-
globin genes interact with each another via the formation of chromatin loops, which occurs at 
the same with the transcription process (Vernimmen et al., 2007).   
 
 
Figure 2.2. Schematic representation of the human α globin gene clusters. The α globin gene 
cluster is situated near the telomeric region, arranged in δ, α2, α1 of the short arm of 
chromosome 16 (Steensma et al., 2005).  
 
The β-like gene cluster is located on the short arm of chromosome 11 (11p15.5). This gene 
cluster also contains embryonic ε, foetal G-gamma (Gγ) and A-gamma (Aγ) and pseudogenes 
which is arranged according to the developmental expression as shown in Figure 2.3. The gene 
expression is regulated by adjacent 5’ promoter in which the TATA, CAAT, and duplicated 
CACCC boxes are located. The locus control region (LCR) is located in this region which 
contain hypersensitive site (HS) which is the hallmark for DNA-protein interaction and 
important for the control of β globin gene expression (Cao and Galanello, 2010). 
Figure 2.3. Schematic representation of the human β globin gene clusters. The β globin gene 




The appropriate α and β genes expression is regulated accordingly to maintain the normal 
production of α- and β-like globin chains for normal haemoglobin production. This regulatory 
mechanisms occur at several levels, mostly during transcription level but with some adjustment 
during and after translation level (A. Victor Hoffbrand, 2016).  
 
2.2 Inherited haemoglobin disorders 
There are 2 main groups of inherited haemoglobin disorders;  
1) Structural haemoglobin variants (haemoglobinopathies) 
2) Thalassaemia 
 
The structural haemoglobin variants are mostly due to single amino acid substitution in the  α or 
β chains (Weatherall and Clegg, 2008). There are more than 1000 different 
haemoglobinopathies have been identified (Steinberg et al., 2009). However the most frequently 
found structural haemoglobin variants are Haemoglobin S (HbS), Haemoglobin C (HbC) and 
HbE variants. HbE is the commonest haemoglobin variant found globally (Rees et al., 1998).  
 
The thalassaemia is due to reduce or absent of the normal globin chain synthesis either due to 
mutation or deletion of the affected genes. It is broadly classified according to the affected 
globin chain that is ineffectively synthesized into α, β, delta/beta- (δβ) and εδβ- thalassaemia 






2.3 Alpha thalassaemia 
Alpha thalassaemia is caused by reduction or absent of α globin chains. It is most frequently 
caused by deletion of one or both α globin genes and less commonly by mutational defects 
(Galanello and Cao, 2011).  
 
2.3.1 Pathophysiology of α thalassaemia 
The α genes are located on the short arm of chromosome 16 (16p13.3). The molecular 
pathology of the α thalassaemia is more complicated than β thalassaemia as normal human 
received 2 copies of gene from each parent (Weatherall and Clegg, 2001). Normal individual 
carries 4 functional α globin genes, designated as αα/αα. Reduce in α globin chain synthesis 
either due to deletion or mutation of the globin genes leads to α thalassaemia. There are 2 main 
classes of α thalassaemia, the alpha zero (α
0
) and alpha plus (α
+
) (Higgs and Weatherall, 2009). 
The α
0 
thalassaemia is a state where both α genes in one chromosome are deleted, either all or 
part of genes are missing. The heterozygotes state of α
0
 is labelled as αα/--, while homozygotes 
is --/--.  In α
+
 thalassaemia, there is only one gene in one chromosome is lost or inactivated. The 
heterozygotes state is labelled as αα/-α while homozygotes is -α/-α. In some α
+
 thalassaemia 







α in homozygous individual (Harteveld and Higgs, 2010). In Malaysian 





 thalassaemia (George, 1998). 
 
2.3.2 Types of deletional α thalassaemia and its worldwide distribution 
The α
0
 thalassaemia is commonly resulting from deletion of 17.5 kb to 20 kb of both duplicated 











 thalassaemia, there is extensive deletion of α 
11 
 
globin gene involving the δ globin gene. This α
0 
thalassaemia is found at highest frequency in 
South East Asia, in which more than 10% of the population are carriers in some regions. It is 
also commonly found in the Eastern Mediterranean Island and mainland population but reported 




 thalassaemia is caused by deletion of one globin gene in one chromosome. There are 2 
common types of α
+
 thalassaemia have been observed, the leftward 4.2 kb gene deletion (α-
4.2
) 




thalassaemia, there is reciprocal 
recombination between highly homologous regions called Z boxes resulting the specific 
deletion, leaving only one normal gene reserved. In α-
4.2 
thalassaemia, there is recombination 
between mispaired homologous X boxes producing the characteristic deletion as shown in 
Figure 2.4 (Embury et al., 1980).  
 
 
Figure 2.4. The molecular mechanism that underlie the deletion forms of α
+ 
thalassaemia 
(a) normal cluster showing X, Y and Z homology boxes 
(b) 3.7-kb deletion 
(c) 4.2-kb deletion 






 thalassaemia has a worldwide distribution with the most frequently found is the 
rightward 3.7 kb gene deletion. In Malaysian population, α thalassaemia is most commonly due 




 thalassaemia (George, 1998). Population studies have 
indicated that the types and frequencies of the different α thalassaemia defects vary among 
different ethnic communities and tend to be geographically specific (Rahimah et al., 2012).  
 
2.3.3 Genotypic and phenotypic characteristics of α thalassaemia 
The affected individual can have variable phenotypic expression depends on the number of the 
affected genes as well as the type of deletion or mutation involved (Leung et al., 2008).  The 
inheritance of α thalassaemia genes and its probable phenotype is represented in Figure 2.5. 
Individual with one gene deletion (-α/αα) or two genes deletion either heterozygous α
0
 (--/αα) or 
homozygous α
+
 (-α/-α) is usually asymptomatic. However, some might have borderline 
hypochromic microcytic red blood cells or anaemia (Higgs, 2001). Individuals with three genes 
deletion (--/-α) have thalassaemia intermedia picture characterised by moderate anaemia, 
marked hypochromic microcytic red cells and increased in spleen size (Chen et al., 2000). 
When only one functional α globin gene is inherited, this results in HbH disease. This is usually 




 thalassaemia (Ahmad et al., 2013). 
Patient with HbH disease is presented with variable severity of chronic haemolytic anaemia. It 
is characterized by greatly reduced rate of synthesis of α chain, imbalance and excess of β chain 
production which lead to the formation of an abnormal haemoglobin with β chain tetramers 
referred to as HbH. This HbH is unstable and precipitates in erythroblasts and results in 
haemolysis and intramedullary cell death or also referred to as ineffective erythropoiesis (A. 





Complete four α genes deletion (--/--) leads to Haemoglobin Bart’s hydrops foetalis which 
causes severe intrauterine anaemia, resulting death in late gestation or shortly after birth. This 
sometimes leads to maternal obstetric complications including pre-eclampsia, antepartum and 
postpartum haemorrhage as well as premature onset of labour (Liang et al., 1985). This 
condition is not compatible with extra uterine life (Harteveld and Higgs, 2010).  
 
 
Figure 2.5. The genetics of α thalassaemia. Adapted from (A. Victor Hoffbrand, 2016). 
 
2.4 Beta thalassaemia 
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Beta thalassaemia is caused by reduction or absent of the β globin chains. It has very variable 
clinical phenotypic based on the rate of imbalance between α and β globin chains (Cao and 
Galanello, 2010).  
 
 
2.4.1 Pathophysiology of β thalassaemia 
Beta globin gene (HBB) is located on the short arm of chromosome 11 (11p15). Normal 
individual carries 2 functional globin genes, termed as β/β. Reduce in the β globin chain 
synthesis leads to β thalassaemia. Beta thalassaemia is commonly caused by point mutation of 
the involved gene and rarely due to extensive deletions (Cao and Galanello, 2010). As with α 
thalassaemia, it is classified as beta zero (β
0
) and beta plus (β
+
) thalassaemia. The β
0
 
thalassaemia is characterised by total absence of the involved β gene while the β
+
 thalassaemia 
is characterised by reduce in the amount of the globin chains produced (Musallam et al., 2013). 
The heterozygotes state
 



















 (Schrier et al., 2014). 
 
2.4.2 Types of β thalassaemia and its worldwide distribution 
The β thalassaemia is a heterogeneous disease at molecular level with more than 200 mutations 
have been so far identified. Majority of cases are single nucleotide point mutation including 
insertion, substitution or deletion leading to a frameshift. Generally, the mutations are divided 
into 3 categories;  
1) Mutations leading to defective β gene transcription (promoter and 5’ Untranslated Region 
(UTR) mutations);  
15 
 
2) Mutations affecting messenger RNA (mRNA) processing (splice junction and consensus 
sequence mutations, polyadenylation, and other 3’ UTR mutations); and  
3) Mutations resulting in abnormal mRNA translation (nonsense, frameshift and initiation 
codon mutations) (Cao and Galanello, 2010).   
 
Beta thalassaemia is inherited as autosomal recessive and is present with high prevalence in the 
Mediterranean, Middle-East, Central Asia, Indian subcontinent and Far East. The highest 
incidence of β thalassaemia are reported in Sardinia (19%), Cyprus (17%), and Greece (19%) 
(Weatherall and Clegg, 2001). 
 
2.4.3 Genotypic and phenotypic characteristics of β thalassaemia 
The β thalassaemia has variable clinical severity based on the degree of affected β globin chain 
synthesis. There are 3 recognised clinical and haematological conditions of β thalassaemia 
which are the β thalassaemia carrier, β thalassaemia intermedia and β thalassaemia major. The β 
thalassaemia carrier state is characterised by having hypochromic microcytic red blood cells 
indices with marked variation of size and shape, but clinically asymptomatic. It is resulted from 
heterozygosity for β thalassaemia (Weatherall and Clegg, 2001).  
 
The homozygosity for β thalassaemia results in β thalassaemia intermedia or thalassaemia 
major. The β thalassemia major affected individual is usually presented with severe transfusion 
dependent anaemia within first 2 years of life (Danjou et al., 2011) . Haematological parameters 
show a severe hypochromic microcytic anaemia and presence of nucleated red blood cells with 
anisocytosis and poikilocytosis on peripheral blood smear. The number of nucleated red blood 
cells is related to the degree of anaemia and is markedly increased after splenectomy (Cao and 




Individual with β thalassaemia intermedia shows a markedly heterogeneous clinical picture and 
genotypic expression, ranging from asymptomatic thalassaemia carrier to severe transfusion 
dependent state. The transfusion dependent individual generally present later in life (aged 2-6 
years) in comparison to those with thalassaemia major (Higgs et al., 2012).  The affected 
individual has a moderate anaemia and shows a markedly heterogeneous haematological 
picture, ranging from that of β thalassaemia carrier state to that of thalassaemia major (Cao and 
Galanello, 2010).  
 
The allelic heterogeneity at β globin locus gives rise to a variable clinical severity of β 
thalassaemia. It is mainly related to the extent of imbalance between α globin chains and non-α 
chains (Danjou et al., 2011). The clinical phenotype is also modified by genetic factors mapping 
outside the globin gene clusters and not influencing the foetal haemoglobin including those 
affecting bilirubin, iron and bone metabolisms (Cao and Galanello, 2010).  
 
2.5 Effect of coinheritance for thalassaemia 
The coinheritance of β thalassaemia with α thalassaemia may change the haematological 
parameters and the phenotypic characteristic of the condition. This may lead to misdiagnosis 
during routine investigations.  
 
A case reported by E. Kanavakis et al describing a case of coinheritance of severe form of β 
thalassaemia and α thalassaemia which interacted in synergistic manner to balance the 
phenotype of classic thalassaemia syndrome. The patient was first hospitalised at the age of 50 
years old for 2 days with presenting symptoms of fatigue in the constitutional symptoms and 
apparent absence of other thalassaemia major or intermedia associated clinical manifestations 
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such as jaundice, growth retardation or bone deformities. Full blood counts demonstrated a 
severe anaemia (haemoglobin 5.4 g/dL) with extremely low red cell indices (MCV 48.7 fL and 
MCH 13.9 pg) and blood film examination found significant hypochromic microcytic red blood 
cells. No inclusion was detected with methyl violet incubation. Patient’s DNA analysis showed 





Overall, the case had a well-compensated anaemia with mild expression of the symptoms of 
thalassaemia such as ineffective erythropoiesis and oxidative stress. It was concluded that 
coinheritance of severe form of β thalassaemia and α thalassaemia interacted in a synergistic 
manner, which almost complete negated the symptoms of classic thalassaemia syndromes 
(Kanavakis et al., 2004).  
 
Another study by O. Sripichai et al at Mahidol University (Thailand) assessing the effect for α 
globin gene copy number in modifying β thalassaemia disease severity by studying 925 cases of 
β
0
 thalassaemia and HbE patients aged 2 to 77 years old in Thailand. In this study, they found 
that 7.9% (73 of 925) of the cohort with haemoglobin level > 7.5 g/dl, MCV < 60 fl, and HbF < 
30%, and out of this 73 cases, 55 cases (75.3%) were found to have α thalassaemia 
coinheritance. This study also clearly demonstrated that a depletion of α globin chains could 
ameliorate the effect of excess α globin chains in β
0
/HbE patients (Sripichai et al., 2008). 
 
Melis et al concluded that the interaction of heterozygous β
0
 thalassaemia with deletion of one 
or two α genes may produce normal red cell indices. They found that normal red cell indices in 
several β thalassaemia heterozygotes seem to represent the maximum expression of the 
ameliorating tendency due to the coinheritance of α thalassaemia. Therefore, it is advisable to 
incorporate testing for HbA2 value in the first screening test set for β thalassaemia in the 
population where both α and β thalassaemia is prevalent as screening based on MCV/MCH 







2.6 Prevalence of thalassaemia  
It is estimated that approximately 7% of the world population are thalassaemia carriers and 
about 300 000 to 500 00 babies were born with clinically identifiable and significant 
haemoglobin disorders each year with approximately 80% of affected children are born in 
countries classified as low income (Organization, 1985). Generally, this condition is most 
prevalent in tropical region, including Mediterranean Sea, the Middle East and South East Asia. 
However, this condition could now be encountered in most countries due to population 
migrations (Weatherall and Clegg, 2001). 
 
2.6.1 Prevalence of thalassaemia in Malaysia 
It is estimated that the Malaysian population in 2017 is at 32.0 million with 28.7 million are 
citizens and 3.3 million are non-citizens. Malays and other Bumiputera comprised of 68.8%, 
23.2% are Chinese, 7.0% are Indians and other races make up 1.0% of the population 
(Department of Statistics Malaysia, 2017).  
 
In Malaysia, α thalassaemia, HbE and β thalassaemia are prevalent. According to Malaysian 
Thalassaemia Registry 2017, a total of 7220 patients with thalassaemia are registered with 2611 
cases are β thalassaemia major, 2402 cases of HbE/β thalassaemia, 733 cases of thalassaemia 
intermedia, 1022 cases of HbH disease and 452 cases with other diagnosis. Out of this figure, 
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5013 cases are transfusion dependent thalassaemia, mostly β thalassaemia major and HbE/β 
thalassaemia cases (Malaysian Thalassemia Registry, May 2017).  
 
There are increasing trend of reported cases of thalassaemia in Malaysia over the years. It is 
most probably due to better case reporting, increase number of thalassaemia new birth with less 
mortality and increasing number of survivors because of better treatment. It is estimated that 
about 200 new cases per year are reported. Sabah gives the highest contribution for thalassaemia 
cases in Malaysia with 23.5% of total cases of thalassaemia, followed by Selangor (15%), 
Kedah (9.4%) and Kuala Lumpur (8%) (Malaysian Thalassemia Registry, May 2017).  
 
Various ethnic groups exhibit unique phenotypes and genotypes characteristic of thalassaemia 
distribution. β thalassaemia major is more prevalent in Kadazan ethnic of Sabahan, while HbE-β 
thalassaemia is more commonly seen in Malays and HbH disease is seen commonly in Chinese 
(Malaysian Thalassemia Registry, 2010). 
 
2.6.2 α thalassaemia in Malaysia 
The α thalassaemia is highly prevalent in Malaysia with the prevalence is up to 51.2%. There 











; and 3 non-deletional 
mutation, codon59G>A (Haemoglobin Adana), codon125T>C (Haemoglobin Quong Sze) and 
codon142 (Haemoglobin Constant Spring). The high incidence of -α
3.7
 was observed in Malays, 
Indians, Sabahans, Sarawakians and Aborigines. In Chinese population, --
SEA
 was the most 
commonly detected, followed by the -α
3.7
 deletion (Ahmad et al., 2013). The -α
3.7
 deletion is 
identified as the most common mutation to produce a genetic disorder and is found to be 
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prevalent in most tropical and subtropical population studied (Galanello and Cao, 2011; 




A study was done in regular blood donors in Kelantan population showed that 9.25% of them 
were detected to have deletional α thalassaemia with the commonest spectrum was -α
3.7
 detected 
and found in high frequency among Malay compared to other races (Rosnah et al., 2012).  
 
2.6.3 β thalassaemia in Malaysia 
It is estimated that about 4.5% of Malaysian are heterozygous carriers for β thalassaemia. The 
couples are at risk of producing a child with β thalassaemia major where affected births 
annually would be 2.1/1000 live births (George, 2001). In Malaysia, the spectrum of β 
thalassaemia mutations have been systematically delineated since 1984. There are 19 beta 
mutations characterised in Malaysian population with the commonest was codon 26 mutation 
commonly in Malays while codon 41/42 mutation was common in Chinese ethnicity 
(Sivalingam et al., 2012). In Malays, there were three common β gene mutation identified 
which were HbE (codon 26 GAG  AAG), IVS1-5 GC and IVS1-1 GT, responsible for 
about 73.1% of β thalassaemia. In Chinese-Malaysian, there were five common β globin gene 
mutations found which were codon 41/42 (-TCTT), IVS2-654 (CT), -28 (AG), codon 17 
(AT) and codon 71/72 (+A) and these account for about 90% of β thalassaemia. Among the 
Kadazan-Dusun of Sabah population, the commonest mutation found was the 45kb Filipino 
deletion, a β
0 
thalassaemia phenotype and accounted for over 90% of transfusion dependent 
thalassaemia cases (Elizabeth and Ann, 2010). Other β gene mutations found included codon 








2.7 Disease burden 
Thalassaemia major, if left untreated, results in death in the first few years of life. Their effect 
on the burden of health care is only now being appreciated in many parts of the world. 
Improvements in hygiene, nutrition and control of infection reduce childhood mortality rates. 
These lead to babies with severe haemoglobin disorders to survive long enough and present for 
diagnosis and treatment (Weatherall and Clegg, 2001).  
 
Thalassaemia is a burden to the country. It is estimated that approximately about RM 3 million 
is needed for treatment of thalassaemia major patients until they reach the age of 30 years old 
(Ministry Of Health Malaysia, 2016). The costs include tests for diagnosis and monitoring, 
treatment for the disease itself and its complications as well as investigation modalities for 
complications monitoring (Table 2.2).  
 
Table 2.2. Estimated cost for monitoring, treatment and complications monitoring of 
thalassaemia. Adapted from (Ministry Of Health Malaysia, 2016) 
Tests/ items description Estimated cost 
Blood test every 6 months RM 500 
1 blood filter RM70 
1 unit of packed cells RM 200 
1 desferal infusion pump RM 2500 
1 Thalaset needle RM 10 
MRI T2* RM 1200 
 
In transfusion dependent thalassaemia, iron chelation therapy is mandatory. The therapy is 
usually started at the age of 2 to 3 years (Figure 2.6). The cost of each type of iron chelators 
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differs (Table 2.3) and the frequency of its administration adds the cost burden in the 




Table 2.3. The cost for different types of iron chelation therapy. Adapted from (Ministry Of 
Health, 2009) 
Iron Chelators Unit price Drug cost for a 30 kg patient/month 
Deferiprone (Ferriprox) 500 mg = RM 3.32 75 mg/kg/day x 30 kg ~2.5 gm/day 
1 week  = 35 tablets 
4 weeks = 140 tablets x RM 3.32 
              = RM 464.80 
 
Deferiprone (Kelfer) 500 mg = RM 4.18 75 mg/kg/day x 30 kg ~2.5 gm/day 
1 week  = 35 tablets 
4 weeks = 140 tablets x RM 4.18 




500 mg = RM 10.60 40 mg/kg/day x 30 kg ~ 1.5 gm/day 
1 week  = 18 vials 
4 weeks = 72 vials x RM 10.60 
              = RM 763.20 
 
Deferasirox (Exjade) 125 mg = RM 22.79  
500 mg = RM 91.21 
20 mg/kg/day x 30 kg ~ 500mg/day 
For 28 days = RM 91.21 x 28 
tabs/500mg 





Figure 2.6. Algorithm for iron chelation in transfusion dependent thalassaemia. Adapted from 
(Ministry Of Health, 2009) 
Multi organ toxicity often been observed as a complication in transfusion dependent 
thalassaemia patients including endocrine and cardiac problem. Examples of endocrine problem 
include short stature and growth failure, delayed puberty and hypogonadism, hypothyroidism, 
diabetes mellitus, osteoporosis/osteopenia, hypoparathyroidism, hypoadrenalism. Hepatitis B, 
Hepatitis C, HIV and bacterial infection are examples of infection that are implicated in these 
patients, thus affecting the patient’s life as well as the country economics.  
Therefore, it is vital for the health agencies and governments of countries where the 
haemoglobin disorders occur at a high frequency become aware of the future extent of this 





2.8 Screening programme 
Thalassaemia can be identified in the carrier state and most forms can be diagnosed in the 
foetus. Thus it is possible to offer counselling and prenatal diagnosis for parents who wish to 
terminate pregnancies carrying babies with severe forms of the disease. This approach has 
resulted in a major reduction in the birth of new cases in some of the Mediterranean islands and 
in other countries (Cao and Rosatelli, 1993). Diagnosis of thalassaemia and 
haemoglobinopathies can be made by combination of at least 2 different techniques and must be 






2.8.1 Screening tests 
Diagnostic laboratory investigations for thalassaemia and haemoglobinopathy include full blood 
count (FBC), haemoglobin electrophoresis at alkaline pH, sickling test and quantification of 
abnormal HbA2 and HbF, as recommended by International Committee for Standardization in 
Haematology expert panel on thalassaemia and haemoglobinopathy (Clarke and Higgins, 2000). 
 
2.8.1(a) Full blood count (FBC) and peripheral blood film 
The first step for haemoglobin analysis is scrutiny for the red blood cell indices. The red blood 
cells indices are importance for both α and β thalassaemia carrier diagnosis. The value of MCV 
